Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atrauman Ag is a non-adherent, silver-containing wound contact layer designed for the atraumatic treatment of wounds. It consists of a thin polyamide fabric coated with elemental (metallic) silver and impregnated with neutral triglyceride-based lipids. The dressing acts as an antimicrobial barrier by releasing silver ions upon contact with wound exudate, which are bactericidal at the dressing-wound interface. This local release minimizes cytotoxicity while effectively reducing bacterial bioburden in colonized or critically colonized wounds. Atrauman Ag is indicated for chronic wounds such as venous leg ulcers (ulcus cruris), diabetic foot ulcers, pressure ulcers (decubitus), and acute burns up to second degree. It supports moist wound healing, prevents maceration of wound edges, and allows painless dressing changes due to its non-adherent properties. The product must be used in combination with a suitable secondary absorbent dressing[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atrauman Ag.